CancerDrs

Breast Cancer clinical trials in Vermont

4 actively recruiting breast cancer trials at 2 sites across Vermont.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Vermont:
  • Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
  • University of Vermont Medical Center — Burlington, Vermont
  • University of Vermont and State Agricultural College — Burlington, Vermont
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Vermont:
  • Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
  • University of Vermont Medical Center — Burlington, Vermont
  • University of Vermont and State Agricultural College — Burlington, Vermont
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…

Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in Vermont:
  • The University of Vermont Medical Center Inc. — Burlington, Vermont
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Vermont:
  • Central Vermont Medical Center — Berlin Corners, Vermont
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09